Citigroup's Buy Ratings: Ducommun, Textron, and TransDigm
- July 06th, 2023
- 377 views
Ducommun Incorporated (NYSE: DCO), a leading provider of engineering and manufacturing services for aerospace and defense industries, received coverage initiation from Citigroup with a Buy rating and a price target of $65.
Based on Wednesday's closing price of $43.40, the assigned price target suggests a potential upside of $21.60 or approximately 49.77% for $DCO, according to the investment firm's analysis.
Textron Inc. (NYSE: TXT), a multi-industry company known for its diverse portfolio of aerospace, defense, and industrial products, was initiated with a Buy rating by Citigroup, accompanied by a price target of $90.
With $TXT closing at $67.15 on Wednesday, the stated price target indicates a potential upside of $22.85 or around 34.03%, as per Citigroup's view.
TransDigm Group Incorporated (NYSE: TDG), a global designer, producer, and supplier of highly engineered aircraft components, also received coverage initiation from Citigroup with a Buy rating and a price target of $1042.
Despite closing at $886.58 on Wednesday, the assigned price target suggests a potential upside of $155.42 or approximately 17.52% for $TDG, according to the financial services firm's perspective.
The price targets and potential upsides mentioned reflect the assessments and views of Citigroup, representing their analysis and expectations for the potential growth in stock value. Investors are advised to carefully consider these opinions when making investment decisions.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Johnson & Johnson, Charles Schwab, Halliburton: Earnings Preview
January 18th, 2026Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026




Member Login